So far this year, the average stock in the Russell 3,000 is up 0.12%. Â When factoring out Intercept Pharmaceutical's (ICPT) 589% gain already in 2014, however, the average stock in the index is down 0.07% year-to-date.
That's right, ICPT is already up 589.91% in 2014 after gaining 100% in 2013! Â That's what happens when the Data and Safety Monitoring Board stops the testing of your liver disease drug early because it's working too well!
Below is a list of the Russell 3,000 stocks that are already up more than 20% in 2014. Â Along with ICPT, two other stocks are already up more than 100% -- Conatus Pharma (CNAT) and Neurocrine Biosciences (NBIX). Â A common theme stands out in the list below. Â Almost all of the stocks are from the Health Care sector, and more specifically, the Biotech group.
57.3% of the stocks in the Russell 3,000 are down so far year-to-date. Â Below is a list of the biggest losers. Â As shown, Chelsea Therapeutics (CHTP) is down the most with a loss of 45.21%, followed by Cyan (CYNI), support.com (SPRT), BIND Therapeutics (BIND) and Sears Holdings (SHLD). Â Other notable stocks on the list of 2014's biggest losers include JC Penney (JCP), RadioShack (RSH) and Select Comfort (SCSS). Â All of the stocks on the list below are down more than 15% so far this year.
Copyright Š Bespoke Investment Group